CAR-T Cell Therapy
- Elva Chen
- 1 day ago
- 2 min read
![The application of CAR-T cell therapy provides new treatment options for patients. Clinical evidence shows that CAR-T cell therapy has achieved remarkable efficacy in hematological malignancies, with some patients even achieving complete remission. All currently approved cellular products have reported these long term durable responses. Studies show that 83% of lymphoma patients achieve remission after receiving CAR-T cell therapy, of whom 53% achieve complete remission [2].](https://static.wixstatic.com/media/e2d726_be6621158565445dbea6d0a886d1e3c4~mv2.png/v1/fill/w_850,h_572,al_c,q_90,enc_avif,quality_auto/e2d726_be6621158565445dbea6d0a886d1e3c4~mv2.png)
CAR-T (Chimeric Antigen Receptor T-Cell Therapy) is a major breakthrough in personalized cellular immunotherapy for human cancer. It is regarded as one of the effective solutions for the treatment of relapsed or refractory tumors and has been approved for the treatment of hematological malignancies [1]. The “T” in CAR-T refers to T cells, a type of immune cell present in all human bodies. This therapy involves collecting T cells from a patient and modifying them through ex vivo genetic engineering so that the T cells gain the ability to specifically recognize defined tumor targets, becoming CAR-T cells. The “armed” T cells (i.e., CAR-T cells) are then expanded in large numbers and infused back into the patient. The CAR-T cells proliferate in the patient’s body and precisely kill tumor cells.
CAR-T cell therapy is revolutionary because it elicits highly effective and durable clinical responses. Simply put, T cells are genetically modified in the laboratory to detect and fight diseases and infections throughout the body. Each T cell can recognize antigen receptors and eliminate them when the immune system identifies them as abnormal.
The application of CAR-T cell therapy provides new treatment options for patients. Clinical evidence shows that CAR-T cell therapy has achieved remarkable efficacy in hematological malignancies, with some patients even achieving complete remission. All currently approved cellular products have reported these long term durable responses. Studies show that 83% of lymphoma patients achieve remission after receiving CAR-T cell therapy, of whom 53% achieve complete remission [2]. In addition, statistics indicate that CAR-T cell therapy has also achieved significant outcomes in patients with multiple myeloma, with overall response rates ranging from 73% to 98% in trial results [3].
The “living drug” nature of CAR-T cells enables them to expand and persist in patients, thereby providing sustained anti tumor activity [4]. With technological advances, CAR-T cell therapy has continued to improve, enhancing the safety and efficacy of the treatment [5]. Although some obstacles still exist in the practical application of CAR-T in solid tumors, with further research and clinical practice, it is believed that the future development of CAR-T cell therapy will bring curative hope to more patients.
Comments